Promis Diagnostics has recently unveiled EarlyTect BCD, a groundbreaking urine-based test for the early detection of bladder cancer in patients experiencing hematuria.
This unique non-invasive test has received approval from the United States Food and Drug Administration (FDA).
Hematuria, characterized by the presence of blood in the urine, is the most common symptom associated with bladder cancer.
EarlyTect BCD is specifically designed to identify a single epigenetic biomarker called PENK methylation, which is closely associated with bladder cancer.
By analyzing the urine DNA of patients with hematuria, the test can accurately detect the presence of PENK methylation, which is consistently observed in the urine DNA of individuals with bladder malignancies, distinguishing them from hematuria patients without the disease.
The introduction of EarlyTect BCD represents a significant advancement in bladder cancer diagnostics, offering a non-invasive and reliable method for early detection. This breakthrough test has the potential to improve patient outcomes by enabling timely interventions and reducing the need for invasive procedures.